Floatz logo

Kln-1010

Immune System Disease

Kelonia Therapeutics, Inc.gene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Immune System Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
LIDOCAINE
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Strimvelis
Fondazione Telethon
Phase 4B
Evomela
Washington University School of Medicine
Phase 2B

View all 38 →

Same molecule, other indications

Kln-1010 is also rated in:

neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
vascular hemostatic diseaseDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →